Recruiting PHASE1 INTERVENTIONAL 1-arm
NCT06611150
Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
A Phase I Study of Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
Sponsor: Sun Yat-sen University
Conditions
Nasopharyngeal Carcinoma (NPC)
Interventions
Nab-paclitaxel
Updated 1 time since 2024 Last updated: Sep 25, 2024 Started: Aug 2, 2024 Primary completion: Aug 1, 2025 Completion: Aug 1, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06611150, this PHASE1 trial focuses on Nasopharyngeal Carcinoma (NPC) and remains actively recruiting participants. Sponsored by Sun Yat-sen University, it has been updated 1 time since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Sun Yat-sen University
Data source: Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .